Cresset Asset Management LLC Sells 33,523 Shares of Genmab A/S (NASDAQ:GMAB)

Cresset Asset Management LLC lowered its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 56.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 25,752 shares of the company's stock after selling 33,523 shares during the period. Cresset Asset Management LLC's holdings in Genmab A/S were worth $537,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in GMAB. China Universal Asset Management Co. Ltd. boosted its position in Genmab A/S by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company's stock worth $186,000 after acquiring an additional 827 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after buying an additional 939 shares in the last quarter. Lindbrook Capital LLC boosted its stake in Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after purchasing an additional 950 shares during the period. Grandfield & Dodd LLC lifted its stake in shares of Genmab A/S by 4.2% in the 4th quarter. Grandfield & Dodd LLC now owns 33,733 shares of the company's stock worth $704,000 after acquiring an additional 1,370 shares during the period. Finally, Blue Trust Inc. lifted its holdings in shares of Genmab A/S by 33.4% in the fourth quarter. Blue Trust Inc. now owns 5,757 shares of the company's stock valued at $120,000 after purchasing an additional 1,442 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Price Performance

Genmab A/S stock traded up $0.23 during midday trading on Friday, reaching $19.88. The stock had a trading volume of 836,564 shares, compared to its average volume of 1,112,041. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $30.06. The firm has a market cap of $12.75 billion, a price-to-earnings ratio of 11.43, a PEG ratio of 2.65 and a beta of 1.04. The firm's fifty day simple moving average is $19.74 and its two-hundred day simple moving average is $20.75.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. The business had revenue of $715.00 million for the quarter, compared to the consensus estimate of $5.17 billion. As a group, sell-side analysts predict that Genmab A/S will post 1.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

GMAB has been the subject of several research reports. Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a research note on Thursday, February 13th. Truist Financial decreased their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. Leerink Partnrs upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. Finally, Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $39.17.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.